Abstract
Opioid overdose deaths increased substantially during the COVID-19 pandemic, even as policy changes were implemented to facilitate better access to medications for opioid use disorder (MOUD). While prior work has suggested relatively stable sales volume of buprenorphine, a safe and effective FDA-approved MOUD, among adults during 2020-2021, less is known regarding whether the pandemic has been associated with changes in the use of buprenorphine to treat opioid use disorder among adolescents and young adults (AYA).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
